Added to YB: 2025-10-28
Pitch date: 2025-10-24
CCCC [bullish]
C4 Therapeutics, Inc.
-5.45%
current return
Author Info
Ridire Research is an independent equity research platform focused on actionable, high-conviction long/short equity ideas. We combine fundamental rigor with quantitative structure to identify mispriced opportunities others overlook. Sign up for the newsletter.
Company Info
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins.
Market Cap
$239.4M
Pitch Price
$2.57
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.94
P/E
-1.48
EV/Sales
3.36
Sector
Biotechnology
Category
growth
C4 Therapeutics (CCCC): Targeted Protein Degraders (TPD)
CCCC: TPD pioneer w/ proprietary TORPEDO platform targeting orphan oncology. CFT8634 (synovial sarcoma) & CFT7455 (multiple myeloma) offer 7yr exclusivity + pricing power. Pfizer/Biogen partnerships provide validation & milestone funding. Key risks: class toxicity, ligase resistance. Moats: IP fortress, rare disease focus, capital discipline vs broader competitors.
Read full article (3 min)